Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac

Version 1 : Received: 8 February 2024 / Approved: 9 February 2024 / Online: 9 February 2024 (09:16:59 CET)

How to cite: Díaz-Dinamarca, D.; Cárdenas-Cáceres, S.; Muena, N.A.; Diaz, P.; Barra, G.; Puentes, R.; Escobar, D.F.; Díaz-Samirin, M.; Alay, N.S.; Canales, C.; Díaz, J.; García-Escorza, H.E.; Grifoni, A.; Sette, A.; Tischler, N.D.; Vasquez, A.E. Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac. Preprints 2024, 2024020541. https://doi.org/10.20944/preprints202402.0541.v1 Díaz-Dinamarca, D.; Cárdenas-Cáceres, S.; Muena, N.A.; Diaz, P.; Barra, G.; Puentes, R.; Escobar, D.F.; Díaz-Samirin, M.; Alay, N.S.; Canales, C.; Díaz, J.; García-Escorza, H.E.; Grifoni, A.; Sette, A.; Tischler, N.D.; Vasquez, A.E. Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac. Preprints 2024, 2024020541. https://doi.org/10.20944/preprints202402.0541.v1

Abstract

The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19—associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are among the top most widely used COVID-19 vaccines. Much less is known on the Wuhan-Hu-1 strain based vaccines in the pediatric population compared to adults. Given the worldwide need for booster vaccinations to stimulate the immune response against new Omicron variants of SARS-CoV-2, we characterized the humoral and cellular immune response against Omicron variant BA.1 in a pediatric population aged 10 to 16 years who received heterologous vaccination based on two doses CoronaVac, two doses CoronaVac (2x) plus one booster doses BNT162b2 [CoronaVac(2x) + BNT162b2 (1x)], two doses CoronaVac plus two booster doses BNT162b2 [CoronaVac(2x) + BNT162b2 (2x)], and three doses BNT162b2. We observed that [CoronaVac(2x) + BNT162b2 (2x)] vaccination showed higher anti-S1 and neutralizing antibody titers and CD4 and CD8 T cell immunity specific to the Omicron variant compared to immunization with two doses CoronaVac alone. Furthermore, from all groups tested, immunity against Omicron was highest in individuals who received three doses BNT162b2. We conclude that booster vaccination with BNT162b2 promotes greater immunity against SARS-CoV-2 in the pediatric population compared to two doses CoronaVac alone.

Keywords

SARS-CoV-2; SARS-CoV-2 neutralizing antibodies; COVID-19; Pediatric Population; BNT162b2 (Pfizer-BioNTech); CoronaVac (Sinovac); Heterologous vaccination; Chile

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.